Happy Thursday! Fintechs are building AI solutions to help boost the creditworthiness of borrowers. This and more in today’s ETtech Morning...

Several companies in corporate India, including Infosys, Capgemini, Ericsson, and EY Global Delivery Services, are taking steps to reduce t...

RBI urged people to exercise utmost caution while using such application/s, dealing with and before parting with their money to any such un...

Uber drivers can rent a Tesla through Hertz starting on Nov. 1 in Los Angeles, San Francisco, San Diego and Washington DC, with the program...

A section of Harley-Davidson dealers said continuing with many recently opened showrooms may not be viable, especially in smaller towns and...

As long as it lower support at 11,150-11,100 levels holds, there is a possibility of further upside in the market in the short term.

A recent report by Dutch location and navigation services provider TomTom had found Bengaluru to be the most traffic-congested city in the ...

Startups focus on carpools, buses and corporate services to make ride to work peaceful.

Narrowing margins, demand slump and policy surprises are hurting the stock.

Another area seeing investor action is car & bike pooling, where Quick Ride is learned to have got around $15 million from Naspers.

This may be the first institutional capital raised by sRide, which has mostly been bootstrapped.

Buy Strides Shasun Ltd. at a price target of Rs 990.

Technological change makes the future of oil bleaker by the day. One analyst, Tony Seba, predicts that world demand for oil will peak by 20...

Carpooling is one option that has especially emerged as a favourite among companies and firms with ride-sharing apps are relishing the mome...

Strides Arcolab said its consolidated profit surged to Rs 68.41 crore for the fourth quarter ended December 31, on forex gains and robust s...

If the bank maintains its growth rate, the stock price will continue to rise in line with its financial performance.

Bilcare, the Rs 1,000-crore supplier of technology-driven niche pharma solutions, appears to be a promising bet in the mid-cap segment.